Cancer Research includes companies working on scientific research aimed at understanding the causes, prevention, diagnosis, treatment, and potential cures for cancer. It includes many disciplines, from biology and genetics, to clinical trials and drug development, with the ultimate goal of improving cancer care and outcomes. Cancer research companies are developing life-saving treatments and diagnostics for a growing market in high demand. These companies constantly innovate, have a global reach, and form important strategic partnerships, which makes them appealing to investors looking for profits and supporting health progress.
Pfizer, L3Harris Technologies And More: CNBC's 'Final Trades'
Joshua Brown of Ritholtz Wealth Management named Pfizer Inc. (NYSE:PFE) as his final trade on the latest edition of CNBC's "Halftime Report Final Trades." On Thursday, Pfizer announced it will
Biogen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/12/2024 32.35% Piper Sandler $335 → $313 Maintains Overweight 06/28/2024 24.32% Needham $294 → $294
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
Friday, Immutep Limited (NASDAQ:IMMP) released results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase 2b trial of eftilagimod alfa (efti) in combination with Merck & Co Inc (NYSE:MRK) Keytruda (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression.
This Weight Loss Stock Is the Best Alternative to Eli Lilly, Novo - SA Sentiment
Eli Lilly, Novo Nordisk Shares Dip as Pfizer Ramps Up Diabetes Drug Competition
Shares of $Eli Lilly and Co(LLY.US)$ and $Novo-Nordisk A/S(NVO.US)$ finished lower on Thursday, perhaps influenced by competitive developments and regulatory updates in the pharmaceutical sector.
Gilead Sciences's Options Frenzy: What You Need to Know
Deep-pocketed investors have adopted a bearish approach towards Gilead Sciences (NASDAQ:GILD), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga
Beyond The Numbers: 6 Analysts Discuss Merck & Co Stock
During the last three months, 6 analysts shared their evaluations of Merck & Co (NYSE:MRK), revealing diverse outlooks from bullish to bearish.The table below summarizes their recent ratings,
The weight-loss drug market is too lucrative to be abandoned! After being hit, Pfizer has restarted.
Pfizer, a world-renowned pharmaceutical company, has decided to enter the lucrative weight loss drug market to improve its performance, which has been affected by the post-pandemic slump. Pfizer first evaluated the prospects of the weight loss drug market and estimated that the market will grow to around USD 130 billion in the next ten years, with oral tablets expected to account for about one-third of the market. As a result, Pfizer hopes to compete with Novo Nordisk and Eli Lilly and Co.'s popular injectable weight loss drugs by developing an oral weight loss drug called danuglipron. This oral weight loss drug does not require injections and is expected to rival traditional injectable drugs. However, Pfizer has been struggling to make progress in treating obesity.
Why Pfizer Stock Is Moving Higher on Thursday
Pfizer (NYSE:PFE) stock gained on Thursday after the company announced it will advance development of its once-daily Danuglipron.
Merck & Co Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 4.86% Morgan Stanley $132 → $134 Maintains Equal-Weight 06/20/2024 21.29% Cantor Fitzgerald $15
United Therapeutics Cut at Morgan Stanley on Risk-reward Setup
4 Stocks to Watch on Thursday: PEP, PFE and More
CureVac Announced The Latest Trial Dates For Its Ongoing Patent Litigation Against Pfizer/BioNTech In Multiple Geographies, Including The U.S., UK, And Germany
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology)
Pfizer Advances Development of Once-daily Weight-loss Pill
Bristol-Myers Squibb Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 -0.15% Barclays $43 → $41 Maintains Equal-Weight 04/26/2024 16.9% BMO Capital $55 → $48
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity
Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good
This week, Pfizer Inc (NYSE:PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European industry peer specialized in early detection of cancer, Mainz Biomed N.V. (NASDAQ:MYNZ) applied for Breakthrough Device Designation to the US Food and Drug Administration (FDA) for its revolutionary colorectal cancer (CRC) screening test, which subject to the review, would significantly accelerate the approval process.
Oppenheimer's Best 'SMID-cap' Ideas for 2024
Spotlight on Bristol-Myers Squibb: Analyzing the Surge in Options Activity
Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb (NYSE:BMY), and it's something market players shouldn't ignore. Our tracking of public options records at
Pfizer Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 60.11% Cantor Fitzgerald $45 → $45 Reiterates Overweight → Overweight 07/01/2024 60.11%